Cofoe Medical Technology Co., Ltd. Announces Offer Price for H Shares – Key Investor Information

Key Points from the Announcement

• Offer Price Set: The offer price for Cofoe Medical Technology Co., Ltd. H Shares has been determined at HK\$39.33 per H Share. This price excludes brokerage (1%), SFC transaction levy (0.0027%), Stock Exchange trading fee (0.00565%), and AFRC transaction levy (0.00015%).
• Trading Information: The H Shares are expected to begin trading on the Main Board of the Stock Exchange at 9:00 a.m. on Wednesday, May 6, 2026 (Hong Kong time). The shares will be traded in board lots of 100 H Shares each, with the stock code 1187.
• Global Offering Details: The announcement confirms the Global Offering, subject to the offering becoming unconditional at or before 8:00 a.m. on May 6, 2026. The results of the allocations and indications of interest for both the International Offering and Hong Kong Public Offering will be published on Tuesday, May 5, 2026.
• Key Dates:
  • Prospectus Date: April 27, 2026
  • Offer Price Determination: May 3, 2026
  • Results Announcement: May 5, 2026
  • Listing and Trading Begins: May 6, 2026
• Board Composition: As of May 4, 2026, the board consists of Mr. ZHANG Min (Executive Director and Chairman), Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao, Mr. HE Bangjie (Executive Directors), and Mr. NING Huabo, Ms. SHEN Nan, Mr. Zhou Rong (Independent Non-Executive Directors).

Important Information for Shareholders and Potential Investors

• Termination Risk: The Sponsor-Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) have the right to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect if certain events occur prior to 8:00 a.m. on the Listing Date. This could materially affect the Global Offering and subsequent trading of H Shares.
• Regulatory Restrictions: The securities will not be offered in the United States and are subject to strict regulatory restrictions. The offering is conducted outside the United States in accordance with Regulation S under the U.S. Securities Act of 1933. There will be no public offer in the U.S., and the Company is not registered under the U.S. Investment Company Act of 1940.
• Potential Price Sensitivity:
  • Offer Price Disclosure: The announcement of the offer price (HK\$39.33) is significant and may influence market sentiment and trading activity upon listing.
  • Public Allocation Results: Details surrounding allocation and demand for shares in the Hong Kong Public Offering and International Offering will be published, which may impact initial trading volumes and price volatility.
  • Unconditional Listing: If the Global Offering does not become unconditional, trading will not commence as scheduled, which could have a direct impact on investor confidence and share price.
• Board Lot Size: Investors should note that trading will occur in board lots of 100 H Shares, which can affect liquidity and trading strategies.

Additional Details for Investors

• Timelines for Disclosure: All critical information regarding allocation, demand, and results will be disclosed according to the Prospectus and published through official channels. Investors should monitor these disclosures closely for any developments.
• Corporate Governance: The board composition, including both executive and independent non-executive directors, is in place to oversee governance and strategic direction.
• Usage of Proceeds: Although not detailed in this announcement, investors are encouraged to review the Prospectus for information on the intended use of proceeds from the Global Offering.

Potential Price-Moving Factors

• The confirmed offer price and trading commencement date are likely to influence the share price upon listing.
• Termination of the underwriting agreement prior to listing would be highly price-sensitive and could negatively impact the share value.
• Demand and allocation results for the offering, once published, may drive significant investor interest or caution.

Disclaimer

This article is provided for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should read the full Prospectus and consult their financial advisors before making any investment decisions. The information presented here is based on official announcements and may be subject to change or further clarification by the Company or regulatory authorities.

View COFOE MEDICAL Historical chart here